0001209191-20-007525.txt : 20200207 0001209191-20-007525.hdr.sgml : 20200207 20200207162847 ACCESSION NUMBER: 0001209191-20-007525 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200205 FILED AS OF DATE: 20200207 DATE AS OF CHANGE: 20200207 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Tatsis Ourania CENTRAL INDEX KEY: 0001789815 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 20587854 MAIL ADDRESS: STREET 1: C/O VERTEX PHARMACEUTICALS, INC. STREET 2: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-02-05 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001789815 Tatsis Ourania C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 SVP, CRO Common Stock 2020-02-05 4 A 0 3500 0.00 A 10752 D Common Stock 2020-02-05 4 A 0 6194 0.00 A 16946 D Common Stock 2020-02-06 4 M 0 559 187.53 A 17505 D Common Stock 2020-02-06 4 M 0 408 155.57 A 17913 D Common Stock 2020-02-06 4 S 0 571 238.77 D 17342 D Common Stock 2020-02-06 4 S 0 240 239.68 D 17102 D Common Stock 2020-02-06 4 S 0 90 240.70 D 17012 D Common Stock 2020-02-06 4 S 0 66 242.47 D 16946 D Stock Option (Right to Buy) 187.53 2020-02-06 4 M 0 559 0.00 D 2029-02-05 Common Stock 559 6704 D Stock Option (Right to Buy) 155.57 2020-02-06 4 M 0 408 0.00 D 2028-02-05 Common Stock 408 3261 D Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020. The earned performance shares will vest in installments beginning on 2/24/2020. Restricted stock unit award that vests in installments beginning on 02/10/2021. Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $238.77 (range $238.20 to $239.14). Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $239.68 (range $239.25 to $240.13). Open market sales reported on this line occurred at a weighted average price of $240.70 (range $240.47 to $241.04). The option vests in 16 quarterly installments from 02/06/2019. The option vests in 16 quarterly installments from 02/06/2018. /s/ Omar White, Attorney-in-Fact 2020-02-07